Yaupon files NDA for mechlorethamine with FDA
Mechlorethamine gel is indicated as a treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). The NDA submission is based in data
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.